INTRODUCTION: The aims of this study were to estimate the prevalence of HIV and hepatitis virus coinfection in the Spanish population and to determine the percentage of patients who are candidates for chronic hepatitis C virus (HCV) treatment and liver transplantation within this population. METHODS: A cross-sectional study was performed in 2002 in two Spanish populations of HIV-infected patients: 1,260 patients from 39 centers throughout Spain (P1) and 1,560 patients from three tertiary teaching hospitals in Madrid (P2). RESULTS: The following hepatitis A virus (HAV), hepatitis B virus (HBV) and HCV serological prevalence were found in the P1 and P2 groups, respectively: HAV-IgG antibodies: 74% and 78%; HBsAg1: 4.9% and 4.8%; HBsAg-, anti-HBc1, anti-HBs1: 39% and 39%; HBsAg-, anti-HBc1, anti-HBs-: 25% and 31%; HBsAg-, anti-HBc-, anti-HBs1: 7% and 8%; HBsAg-, anti-HBc-, anti-HBs-: 22% and 16%. Anti-HCV1: 61% and 65%, respectively. Of the patients with positive HCV serology, 88.8% and 84.6% of each group were positive for HCV-RNA by polymerase chain reaction. Multiple coinfections with hepatitis viruses were found in 3.2% and 2.8%, respectively; of these, 70% and 78% had coinfection with HBV, HCV and HDV. Liver cirrhosis was found in 5.8% and 9.6% of the patients coinfected with HIV and HCV, respectively. Liver transplant was indicated in approximately one out of every six coinfected patients with liver cirrhosis. The 43 and 37% of the HCV coinfected patients were good candidates for anti-HCV treatment, but only 14% and 15% of patients had initiated it. CONCLUSIONS: A high percentage of HIV-infected patients in Spain were coinfected with hepatitis viruses, especially HCV. The number of possible candidates for liver transplantation is rising and could increase in the next few years. In the future, greater efforts to treat HIV-and hepatitis virus-coinfected patients will be required.
INTRODUCTION: The aims of this study were to estimate the prevalence of HIV and hepatitis virus coinfection in the Spanish population and to determine the percentage of patients who are candidates for chronic hepatitis C virus (HCV) treatment and liver transplantation within this population. METHODS: A cross-sectional study was performed in 2002 in two Spanish populations of HIV-infectedpatients: 1,260 patients from 39 centers throughout Spain (P1) and 1,560 patients from three tertiary teaching hospitals in Madrid (P2). RESULTS: The following hepatitis A virus (HAV), hepatitis B virus (HBV) and HCV serological prevalence were found in the P1 and P2 groups, respectively: HAV-IgG antibodies: 74% and 78%; HBsAg1: 4.9% and 4.8%; HBsAg-, anti-HBc1, anti-HBs1: 39% and 39%; HBsAg-, anti-HBc1, anti-HBs-: 25% and 31%; HBsAg-, anti-HBc-, anti-HBs1: 7% and 8%; HBsAg-, anti-HBc-, anti-HBs-: 22% and 16%. Anti-HCV1: 61% and 65%, respectively. Of the patients with positive HCV serology, 88.8% and 84.6% of each group were positive for HCV-RNA by polymerase chain reaction. Multiple coinfections with hepatitis viruses were found in 3.2% and 2.8%, respectively; of these, 70% and 78% had coinfection with HBV, HCV and HDV. Liver cirrhosis was found in 5.8% and 9.6% of the patients coinfected with HIV and HCV, respectively. Liver transplant was indicated in approximately one out of every six coinfected patients with liver cirrhosis. The 43 and 37% of the HCV coinfected patients were good candidates for anti-HCV treatment, but only 14% and 15% of patients had initiated it. CONCLUSIONS: A high percentage of HIV-infectedpatients in Spain were coinfected with hepatitis viruses, especially HCV. The number of possible candidates for liver transplantation is rising and could increase in the next few years. In the future, greater efforts to treat HIV-and hepatitis virus-coinfectedpatients will be required.
Authors: José Medrano; Alejando Álvaro-Meca; Alexandre Boyer; María A Jiménez-Sousa; Salvador Resino Journal: Crit Care Date: 2014-08-27 Impact factor: 9.097
Authors: Juan Berenguer; Inmaculada Jarrín; Leire Pérez-Latorre; Víctor Hontañón; María J Vivancos; Jordi Navarro; María J Téllez; Josep M Guardiola; José A Iribarren; Antonio Rivero-Juárez; Manuel Márquez; Arturo Artero; Luis Morano; Ignacio Santos; Javier Moreno; María C Fariñas; María J Galindo; María A Hernando; Marta Montero; Carmen Cifuentes; Pere Domingo; José Sanz; Lourdes Domíngez; Oscar L Ferrero; Belén De la Fuente; Carmen Rodríguez; Sergio Reus; José Hernández-Quero; Gabriel Gaspar; Laura Pérez-Martínez; Coral García; Lluis Force; Sergio Veloso; Juan E Losa; Josep Vilaró; Enrique Bernal; Sari Arponen; Amat J Ortí; Ángel Chocarro; Ramón Teira; Gerardo Alonso; Rafael Silvariño; Ana Vegas; Paloma Geijo; Josep Bisbe; Herminia Esteban; Juan González-García Journal: Open Forum Infect Dis Date: 2018-01-12 Impact factor: 3.835
Authors: A Rivero-Juarez; L F Lopez-Cortes; M Castaño; D Merino; M Marquez; M Mancebo; F Cuenca-Lopez; P Jimenez-Aguilar; I Lopez-Montesinos; S Lopez-Cardenas; A Collado; M A Lopez-Ruz; M Omar; F Tellez; X Perez-Stachowski; J Hernandez-Quero; J A Girón-Gonzalez; E Fernandez-Fuertes; A Rivero Journal: Eur J Clin Microbiol Infect Dis Date: 2016-10-27 Impact factor: 3.267
Authors: M Fernández-Prada; O D Rodríguez-Fonseca; A M Brandy-García; P Alonso-Penanes; I Huerta-González; F Fernández-Noval Journal: Rev Esp Quimioter Date: 2018-03-19 Impact factor: 1.553
Authors: Juan Berenguer; Juan González Garcia; Chiara Fanciulli; Carmen Busca; María J Vivancos; María J Téllez; Lourdes Domínguez; Pere Domingo; Jordi Navarro; Jesús Santos; José A Iribarren; Luis Morano; Arturo Artero; Javier Moreno; Antonio Rivero-Román; Ignacio Santos; Livia Giner; Carlos Armiñanzas; Marta Montero; Christian Manzardo; Carmen Cifuentes; Coral García; María J Galindo; Oscar L Ferrero; José Sanz; Belén de la Fuente; Carmen Rodríguez; Gabriel Gaspar; Laura Pérez; Juan E Losa; Luis Force; Sergio Veloso; Elisa Martínez-Alfaro; Inmaculada Jarrín; Marta De Miguel Journal: HIV Med Date: 2022-01-17 Impact factor: 3.094
Authors: Juan Berenguer; Antonio Rivero; Inmaculada Jarrín; María J Núñez; María J Vivancos; Manel Crespo; María J Téllez; Pere Domingo; José A Iribarren; Arturo Artero; Manuel Márquez; Ignacio Santos; Javier Moreno; Marta Montero; Juan González-García Journal: Open Forum Infect Dis Date: 2016-03-11 Impact factor: 3.835